HeartFlow provides a non-invasive cardiac test that utilizes advanced medical imaging and artificial intelligence to visualize coronary arteries, enabling precise assessment of plaque and lesion-specific fractional flow reserve (FFR). This technology allows physicians to develop effective treatment plans for cardiovascular disease without the risks and costs associated with invasive procedures.
Funding
$215M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Traditional methods for diagnosing coronary artery disease (CAD) can be inaccurate, leading to both false positives that result in unnecessary invasive procedures and false negatives that leave the disease undetected. These inaccuracies can negatively impact patient outcomes and increase healthcare costs.
Solution
HeartFlow provides a non-invasive cardiac analysis platform that combines advanced medical imaging with artificial intelligence to create a personalized 3D model of a patient's heart. Using standard coronary computed tomography angiography (CCTA) scans, the HeartFlow One platform assesses both the anatomy and physiology of the heart. This enables physicians to quantify plaque, assess blood flow with FFR CT Analysis, and efficiently read CCTAs with Roadmap Analysis, leading to more informed treatment decisions and personalized treatment pathways.
Target Audience
The primary target audience includes cardiologists, radiologists, and other healthcare professionals involved in the diagnosis and management of coronary artery disease, as well as hospitals and clinics offering cardiac care services.
Features
- Roadmap™ Analysis: Facilitates efficient and consistent CCTA reads for early and accurate CAD detection.
- FFR CT Analysis: Assesses blood flow throughout the coronary arteries to determine the potential benefit of revascularization.
- Plaque Analysis: Quantifies and characterizes plaque to inform risk assessment and disease management strategies.
- Non-invasive: Reduces the risks and costs associated with invasive diagnostic procedures.
- Personalized 3D Model: Creates a dynamic, patient-specific representation of the heart for enhanced visualization and understanding.
- Integration with CCTA Scans: Leverages existing imaging workflows for seamless adoption.